相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multicenter Harmonization of 89Zr PET/CT Performance
Nikolaos E. Makris et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Predictive Biomarkers for Bevacizumab: Are We There Yet?
Dipen Maru et al.
CLINICAL CANCER RESEARCH (2013)
89Zr- Bevacizumab PET Imaging in Primary Breast Cancer
Sietske B. M. Gaykema et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
PET imaging with 89Zr: From radiochemistry to the clinic
Melissa A. Deri et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A. M. Van der Veldt et al.
CANCER CELL (2012)
Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model
Arne R. M. van der Bilt et al.
CLINICAL CANCER RESEARCH (2012)
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET
Saiyada N. F. Rizvi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Overview of anti-angiogenic agents in development for ovarian cancer
Robert A. Burger
GYNECOLOGIC ONCOLOGY (2011)
Targeting Angiogenesis in Esophagogastric Adenocarcinoma
Alicia F. C. Okines et al.
ONCOLOGIST (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922
Wouter B. Nagengast et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
Pontus K. E. Boerjesson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Autocrine VEGF signaling is required for vascular homeostasis
Sunyoung Lee et al.
CELL (2007)
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft
Wouter B. Nagengast et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Roles for VEGF in the adult
Arindel S. R. Maharaj et al.
MICROVASCULAR RESEARCH (2007)
Immuno-PET: A navigator in monoclonal antibody development and applications
Guus A. M. S. van Dongen et al.
ONCOLOGIST (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
Lars R. Perk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Vascular endothelial growth factor localization in the adult
ASR Maharaj et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET
I Verel et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
分享论文
